How can I help patients find CAR-T treatment opportunities?

Have the knowledge of CAR-T cell therapy

Browse the official websites about CAR-T therapy

Identify the CAR-T treatment center

Get help from a professional CAR-T treatment team and ask for more

Tab Pic Tab Pic Tab Pic Tab Pic

What can be done to plan and prepare for the CAR-T cell therapy?

  • Confirm that the CAR-T treatment center and hospital, closely contact with the CAR-T treatment team and receive help and support
  • Perform CAR-T treatment-related consultation, examination, and appointment
  • Coordinate the holidays and travel arrangements of nursing staff and patients, and clarify the entry and exit-related precautions
  • Arrange hospitalization, accommodation, etc. (preferably near the hospital)
  • Understand the important information of CAR-T treatment, such as pre-treatment examination and treatment process
  • Understand other CAR-T treatment supports, such as commercial insurance
Pic

What can be done after the end of CAR-T treatment?

  • Understand the related knowledge of adverse reactions of CAR-T cell therapy
  • Pay close attention to the patient's health status and the occurrence of adverse reactions
  • Accompany and help patients with daily activities, take care of the patient's diet and living
  • Live near the hospital for seeking medical attention conveniently at any time
  • Assist patients and CAR-T treatment team for subsequent consultations and follow-ups
Pic

Request a Consultation Now for Car-t therapy for Multiple Myeloma

*Required
Upload case photos for expert advice

Maximum 6 images,3Mb each picture limited
Fucaso® (Equecabtagene Autoleucel Injection)

-- The World's First Approved Fully Human CAR-T Therapy

Breakthrough fully human CAR structure
  • Full epitope of light and heavy chains binds tightly to BCMA
  • Fast dissociation, low exhaustion
  • Low immunogenicity
Durable persistence
  • Median duration of persistence time 419 days
  • 12-month sustained MRD negativity rate 81.7%
  • 12-month PFS rate 85.5%
Strong efficacy
  • ORR 98.9%
  • ≥CR rate 82.4%
  • MRD negativity rate 97.8%
Returning to life upon single-dose treatment
Excellent safety
  • No ≥ Grade 3 ICANS
  • Incidence of ≥ Grade 3
  • No movement/cognitive disorder observed No Parkinson's disease found